PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Price to Earnings Ratio (P/E) on December 30, 2024: -0.16

PainReform Ltd. Price to Earnings Ratio (P/E) is -0.16 on December 30, 2024, a -316,720.00% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

PainReform Ltd. 52-week high Price to Earnings Ratio (P/E) is 0.00 on August 12, 2024, which is 100.00% above the current Price to Earnings Ratio (P/E).
PainReform Ltd. 52-week low Price to Earnings Ratio (P/E) is -0.92 on December 13, 2024, which is -483.16% below the current Price to Earnings Ratio (P/E).
PainReform Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.01.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years